Literature DB >> 21825035

Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice.

Magali Dumont1, Cliona Stack, Ceyhan Elipenahli, Shari Jainuddin, Meri Gerges, Natalia N Starkova, Lichuan Yang, Anatoly A Starkov, Flint Beal.   

Abstract

Abnormal tau accumulation can lead to the development of neurodegenerative diseases. P301S mice overexpress the human tau mutated gene, resulting in tau hyperphosphorylation and tangle formation. Mice also develop synaptic deficits and microglial activation prior to any neurodegeneration and tangles. Oxidative stress can also affect tauopathy. We studied the role of oxidative stress in relationship to behavioral abnormalities and disease progression in P301S mice at 2, 7, and 10 mo of age. At 7 mo of age, P301S mice had behavioral abnormalities, such as hyperactivity and disinhibition. At the same age, we observed increased carbonyls in P301S mitochondria (∼215 and 55% increase, males/females), and deregulation in the activity and content of mitochondrial enzymes involved in reactive oxygen species formation and energy metabolism, such as citrate synthase (∼19 and ∼5% decrease, males/females), MnSOD (∼16% decrease, males only), cytochrome C (∼19% decrease, females only), and cytochrome C oxidase (∼20% increase, females only). These changes in mitochondria proteome appeared before tau hyperphosphorylation and tangle formation, which were observed at 10 mo and were associated with GSK3β activation. At that age, mitochondria proteome deregulation became more apparent in male P301S mitochondria. The data strongly suggest that oxidative stress and mitochondrial abnormalities appear prior to tau pathology.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21825035      PMCID: PMC3205832          DOI: 10.1096/fj.11-186650

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

1.  Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal.

Authors:  M Pérez; R Cuadros; M A Smith; G Perry; J Avila
Journal:  FEBS Lett       Date:  2000-12-15       Impact factor: 4.124

Review 2.  Neurodegenerative tauopathies.

Authors:  V M Lee; M Goedert; J Q Trojanowski
Journal:  Annu Rev Neurosci       Date:  2001       Impact factor: 12.449

Review 3.  Frontotemporal dementia and tauopathy.

Authors:  Y Yoshiyama; V M Lee; J Q Trojanowski
Journal:  Curr Neurol Neurosci Rep       Date:  2001-09       Impact factor: 5.081

Review 4.  Transgenic mouse models of tauopathy in drug discovery.

Authors:  W Noble; D P Hanger; J-M Gallo
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-08       Impact factor: 4.388

5.  Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

Authors:  Brian R Hoover; Miranda N Reed; Jianjun Su; Rachel D Penrod; Linda A Kotilinek; Marianne K Grant; Rose Pitstick; George A Carlson; Lorene M Lanier; Li-Lian Yuan; Karen H Ashe; Dezhi Liao
Journal:  Neuron       Date:  2010-12-22       Impact factor: 17.173

6.  Measurement of mitochondrial ROS production.

Authors:  Anatoly A Starkov
Journal:  Methods Mol Biol       Date:  2010

7.  Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model.

Authors:  Heng Du; Lan Guo; Shiqiang Yan; Alexander A Sosunov; Guy M McKhann; Shirley ShiDu Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-11       Impact factor: 11.205

8.  Mitochondrial permeability transition pore component cyclophilin D distinguishes nigrostriatal dopaminergic death paradigms in the MPTP mouse model of Parkinson's disease.

Authors:  Bobby Thomas; Rebecca Banerjee; Natalia N Starkova; Steven F Zhang; Noel Y Calingasan; Lichuan Yang; Elizabeth Wille; Beverly J Lorenzo; Daniel J Ho; M Flint Beal; Anatoly Starkov
Journal:  Antioxid Redox Signal       Date:  2011-06-16       Impact factor: 8.401

Review 9.  Effects of estrogen in the brain: is it a neuroprotective agent in Alzheimer's disease?

Authors:  Sónia C Correia; Renato X Santos; Susana Cardoso; Cristina Carvalho; Maria S Santos; Catarina R Oliveira; Paula I Moreira
Journal:  Curr Aging Sci       Date:  2010-07

Review 10.  Mitochondrial mechanisms of estrogen neuroprotection.

Authors:  James W Simpkins; Kun Don Yi; Shao-Hua Yang; James A Dykens
Journal:  Biochim Biophys Acta       Date:  2009-11-26
View more
  47 in total

1.  Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer's disease.

Authors:  Moon-Yong Cha; Hyun Jin Cho; Chaeyoung Kim; Yang Ouk Jung; Min Jueng Kang; Melissa E Murray; Hyun Seok Hong; Young-Joo Choi; Heesun Choi; Dong Kyu Kim; Hyunjung Choi; Jisoo Kim; Dennis W Dickson; Hyun Kyu Song; Jin Won Cho; Eugene C Yi; Jungsu Kim; Seok Min Jin; Inhee Mook-Jung
Journal:  Hum Mol Genet       Date:  2015-09-10       Impact factor: 6.150

2.  Caspase-Cleaved Tau Impairs Mitochondrial Dynamics in Alzheimer's Disease.

Authors:  María José Pérez; Katiana Vergara-Pulgar; Claudia Jara; Fabian Cabezas-Opazo; Rodrigo A Quintanilla
Journal:  Mol Neurobiol       Date:  2017-01-13       Impact factor: 5.590

3.  Three weeks of erythropoietin treatment hampers skeletal muscle mitochondrial biogenesis in rats.

Authors:  Vladimir E Martinez-Bello; Fabian Sanchis-Gomar; Marco Romagnoli; Frederic Derbre; Mari Carmen Gomez-Cabrera; Jose Viña
Journal:  J Physiol Biochem       Date:  2012-05-25       Impact factor: 4.158

Review 4.  Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease.

Authors:  Qian Cai; Prasad Tammineni
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

5.  Behavioral improvement after chronic administration of coenzyme Q10 in P301S transgenic mice.

Authors:  Ceyhan Elipenahli; Cliona Stack; Shari Jainuddin; Meri Gerges; Lichuan Yang; Anatoly Starkov; M Flint Beal; Magali Dumont
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

6.  Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy.

Authors:  Sarah L DeVos; Rebecca L Miller; Kathleen M Schoch; Brandon B Holmes; Carey S Kebodeaux; Amy J Wegener; Guo Chen; Tao Shen; Hien Tran; Brandon Nichols; Tom A Zanardi; Holly B Kordasiewicz; Eric E Swayze; C Frank Bennett; Marc I Diamond; Timothy M Miller
Journal:  Sci Transl Med       Date:  2017-01-25       Impact factor: 17.956

7.  Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity.

Authors:  Cliona Stack; Shari Jainuddin; Ceyhan Elipenahli; Meri Gerges; Natalia Starkova; Anatoly A Starkov; Mariona Jové; Manuel Portero-Otin; Nathalie Launay; Aurora Pujol; Navneet Ammal Kaidery; Bobby Thomas; Davide Tampellini; M Flint Beal; Magali Dumont
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 8.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

9.  Bezafibrate administration improves behavioral deficits and tau pathology in P301S mice.

Authors:  Magali Dumont; Cliona Stack; Ceyhan Elipenahli; Shari Jainuddin; Meri Gerges; Natalia Starkova; Noel Y Calingasan; Lichuan Yang; Davide Tampellini; Anatoly A Starkov; Robin B Chan; Gilbert Di Paolo; Aurora Pujol; M Flint Beal
Journal:  Hum Mol Genet       Date:  2012-08-24       Impact factor: 6.150

10.  Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease.

Authors:  Maria Manczak; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2012-08-27       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.